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Background: Chagas cardiomyopathy is caused by Trypanosoma cruzi (Tc). Two
antigenic candidates, TcG2 and TcG4, are recognized by antibodies in naturally infected
dogs and humans; and these vaccine candidates provided protection from Tc infection
in mice and dogs. Trypanosoma rangeli (Tr) is non-pathogenic to mammals and shown
to elicit cross-reactive anti-Tc antibodies. In this study, we investigated if fixed Tr (fTr) can
further enhance the efficacy of the TcG2/TcG4 DNA vaccine.
Methods and Results: C57BL/6 mice were immunized with TcG2/TcG4 DNA
vaccine and fTr (delivered as an adjuvant or in prime-boost approach), and
challenged with Tc. Serology studies showed that fTr (±quil-A) elicited Tc- and
Tr-reactive IgGs that otherwise were not stimulated by TcG2/TcG4 vaccine only,
and quil-A had suppressive effects on fTr-induced IgGs. After challenge infection,
TcG2/TcG4-vaccinated mice exhibited potent expansion of antigen- and Tc-specific
IgGs that were not boosted by fTr±quil-A. Flow cytometry analysis showed that
TcG2/TcG4-induced dendritic cells (DC) and macrophages (Mϕ) responded to challenge
infection by expression of markers of antigen uptake, processing, and presentation, and
production of pro-inflammatory cytokines. TcG2/TcG4-induced CD4+T cells acquired
Th1 phenotype and expressed markers that orchestrate adaptive immunity. A fraction
of vaccine-induced CD4+T cells exhibited iTreg phenotype responsible for aversion
of self-injurious immune responses. Further, TcG2/TcG4-vaccinated mice exhibited
potent expansion of poly-functional CD8+T cells with TNF-α/IFN-γ production and
cytolytic phenotype post-infection. Subsequently, tissue parasites and pathology were
hardly detectable in TcG2/TcG4-vaccinated/infected mice. Inclusion of fTr±quil-A had
no clear additive effects in improving the Tc-specific adaptive immunity and parasite
control than was noted in mice vaccinated with TcG2/TcG4 alone. Non-vaccinated
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mice lacked sufficient activation of Th1 CD4+/CD8+T cells, and exhibited >10-fold
higher levels of tissue parasite burden than was noted in vaccinated/infected mice.
Conclusion: TcG2/TcG4 vaccine elicits highly effective immunity, and inclusion of fTr is
not required to improve the efficacy of DNA vaccine against acute Tc infection in mice.
Keywords: Trypanosoma cruzi, Chagas disease, recombinant DNA vaccine, T. rangeli, immune efficacy
INTRODUCTION
Chagas cardiomyopathy, caused by Trypanosoma cruzi, is
a major health concern in Latin America and it is an
emerging disease in the United States, Europe, Japan, and
other countries (1). The majority of individuals exposed to
T. cruzi remain seropositive for their life. In ∼30% of the
infected individuals, clinical symptoms progress from cardiac
hypertrophic remodeling (i.e., wall thickening) to dilated
cardiomyopathy, and ultimately result in cardiac arrest and
death (2).
The sequencing of T. cruzi genome (3) and the development
of approaches to produce recombinant proteins at low cost have
made it feasible to produce, deliver, and test the efficacy of a
variety of recombinant T. cruzi antigens as potential vaccine
candidates in experimental models of infection and disease. We
have screened several candidate antigens, and selected TcG1,
TcG2, and TcG4 for further development as potential vaccine
candidates. These antigens are phylogenetically conserved in
clinically important T. cruzi strains, expressed in infective and
intracellular stages of the parasite, and recognized by parasite-
specific cellular and humoral immune responses in multiple T.
cruzi-infected hosts (4–7). Further, we showed that prophylactic
immunization with TcG1, TcG2, and TcG4 based subunit
vaccine(s) elicited parasite-specific lytic antibodies and cytolytic
T cell responses, and Th1 cytokines in mice and dogs (8–12).
Recent studies have tested several other antigenic candidates as
vaccine for their prophylactic and therapeutic efficacy against
Chagas disease. Results of these vaccines are encouraging and
summarized in recent reviews (13–15). However, till to date none
of the anti-T. cruzi vaccines have produced sterile immunity in
any of the experimental animal models.
The use of heterologous DNA-prime/inactivated
microorganism-boost vaccine (13) has been previously reported
with promising results. T. rangeli (Tr) exhibits significant
homology (>60%) with T. cruzi proteome (15, 16), but Tr
is not pathogenic for mammals (17, 18), and, therefore, it
can be cultivated in large batches in clean, biosafety level one
laboratory facilities. Studies in mice and dogs have suggested that
immunization with fixed, lysed, or fractionated Tr can provide a
degree of protection from T. cruzi infection and histopathological
lesions produced during Chagas disease (19–21). When used
in combination with a subunit vaccine, booster immunization
with glutaraldehyde fixed T. rangeli (fTr) epimastigotes appeared
to lower the blood parasitemia and tissue parasite foci in dogs
(12). However, the immunological mechanisms that might be
elicited by fTr to provide protection against T. cruzi infection are
not known.
In this study, we aimed to determine if fTr enhances the
efficacy of the DNA vaccine against T. cruzi. For this, we
immunized mice with TcG2/TcG4 DNA and fTr (individually
or in combination, or in a prime-boost approach), and then
challenged with T. cruzi. We analyzed the reactivity of the
vaccine-induced antibody responses against T. cruzi and T.
rangeli, and profiled the activation of antigen presenting cells
(APC), i.e., dendritic cells (DC) and macrophages (Mϕ), and
CD4+ and CD8+ T cells after vaccination and challenge
infection. We also evaluated the efficacy of vaccine compositions
in controlling parasite dissemination in tissues and examined
histopathology of the heart and skeletal muscles, focusing on the
efficacy of vaccination protocol in reducing the tissue injury by
acute T. cruzi infection.
MATERIALS AND METHODS
Ethics Statement
All animal experiments were conducted following the National
Institutes of Health guidelines for housing and care of
laboratory animals and in accordance with protocols approved
by the Institutional Animal Care and Use Committee (protocol
number 08-05-029) at The University of Texas Medical Branch
at Galveston.
All experiments were conducted in ABSL2/BSL2-approved
laboratory and all personnel have received appropriate
ABSL2/BSL2 training.
Vaccine Composition, Immunization, and
Challenge Infection
The cDNAs for TcG2 and TcG4 (Genbank: AY727915
and AY727917, respectively) were cloned in pCDNA3.1
eukaryotic expression plasmid (10). Recombinant plasmids were
transformed into E. coli DH5-alpha-competent cells, grown
in Luria-Bertani broth containing 100µg/ml ampicillin, and
purified by anion exchange chromatography by using a Qiagen
Endofree maxi prep kit (Qiagen, Chatsworth, CA) (4). Purified
plasmids were used at a concentration of 25 µg each plasmid
per vaccination.
T. rangeli (Tr, Guatemala strain) epimastigote cultures were
propagated in LIT media (12). Tr epimastigotes (1 × 109/ml)
were fixed with 0.1% glutaraldehyde solution (Sigma-Aldrich),
washed three times with 1X cold Phosphate Buffered Saline
(PBS). Fixed Tr (fTr) lysate (1× 108 Tr equivalent in 100µl PBS)
was used with or without 5 µg quil A (QA) for vaccination (12).
C57BL/6 female mice (6-week-old) were obtained from
Harlan Labs (Indianapolis, IN). To assess if fTr and Quil A
(QA, saponin) adjuvant the DNA vaccine-induced responses,
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mice were vaccinated in following groups: (1) DNA vaccine only,
two doses; (2) DNA vaccine + fTr, two doses; (3) DNA vaccine
+ QA, two doses; (4) DNA vaccine + fTr + QA, two doses.
To determine if fTr boosts the DNA vaccine-induced immune
responses, mice were vaccinated with DNA vaccine followed
by fTr (gp5) or fTr+QA (gp6). Each dose of DNA vaccine
was constituted of 25-µg of each plasmid (pCDNA3.TcG2 and
pCDNA3.TcG4) and delivered in 100 µl PBS by intramuscular
(im) injection in the hind thighs. When used, fTr (1 × 108 Tr
in 100 µl PBS) was delivered by subcutaneous (sc) injection.
When added, vaccine was emulsified with 5 µg QA per dose
per mouse. Non-vaccinated (N) mice were used as controls.
Prime and booster doses of vaccine were given at 21-day
intervals. Immunized and control mice were euthanized at 21
days’ post-vaccination (pv), and sera, splenocytes, and lymph
node (LN) cells were collected to evaluate the vaccine-induced
immunological responses.
For challenge infection, T. cruzi (Tc) trypomastigotes (Sylvio
X10/4 strain) were maintained and propagated by continuous in
vitro passage in C2C12 cells. We included gp1, gp5, and gp6 for
challenge studies becausemice in these groups exhibitedmaximal
vaccine-induced T cell immunity. Mice were immunized as
above, challenged with Tc (10,000 trypomastigotes/mouse,
intraperitoneal) at 21 days after the 2nd vaccine dose, and
euthanized at 21 days’ post-infection (pi). Non-vaccinated mice
infected with Tc (T) and euthanized at similar time-points were
used as controls. The vaccination and challenge infection scheme
is presented in Figure 1A.
Serology
The cDNAs for TcG2 and TcG4 were cloned in-frame with a C-
terminal His-tag into a pET-22b plasmid (Novagen, Gibbstown,
NJ). Plasmids were transformed in BL21 (DE3) pLysS-competent
cells, and recombinant proteins were purified by using the poly-
histidine fusion, peptide-metal chelation chromatography system
(8, 11). Tc trypomastigotes and Tr epimastigotes (2 × 107 each)
were sonicated in 1mL of 50mM carbonate-bicarbonate buffer
(pH 9.6), and centrifuged for 10min at 10,000 × g at 4◦C. The
supernatants of Tc lysate (TcL) and Tr lysate (TrL) were used as
soluble antigens for serology.
Serum immunoglobulin G (IgG) response was monitored by
an enzyme linked immunosorbent assay (ELISA). Briefly, 96-
well flat-bottom plates (Falcon, Becton Dickinson, Oxnard, CA)
were coated for 2 h with TcL or TrL (5 × 105 protozoans’
equivalent/well) or recombinant TcG2 and TcG4 proteins (10-
µg/ml). Plates were blocked for 1 h with 5% non-fat dry
milk (NFDM, Bio-Rad) in PBS-0.01% Tween 20 (PBST). Plates
were washed and incubated for 2 h with sera from vaccinated,
vaccinated/infected and control mice (1:100–1:1,000 dilutions in
0.5% NFDM, 100 µl/well). To detect the total IgG levels, plates
were then directly incubated for 30min with goat anti-mouse
IgG–horseradish peroxidase (HRP) conjugate. To detect IgG
subtypes, plates were sequentially incubated for 2 h with biotin-
conjugated goat anti-mouse Ig subtypes (IgG1, IgG2a, IgG2b,
or IgG2c), and for 30min with streptavidin-HRP conjugate. All
incubations were carried at 37◦C, and plates were washed at each
step with PBST and PBS. All antibodies were purchased from
Southern Biotech, and used at 1: 5,000 dilutions in PBST-0.5%
NFDM. Color was developed by incubation with 100µl/well Sure
Blue TMB substrate (Kirkegaard & Perry Labs) and recorded at
450 nm by using a SpectraMax M5 microplate reader (Molecular
Devices). In some experiments, sera samples were pre-absorbed
with TcL or TrL for 1 h before use in an ELISA assay (8, 16).
To examine the antigen-avidity index, plates were coated
with TcL as above, blocked with 5% NFDM, and sequentially
incubated with sera samples (1: 100 dilutions in 1% NFDM)
for 1 h, 6M urea for 30min, and HRP-conjugated secondary
antibody for 30min. A colorimetric reaction was performed as
above (% Avidity: [O.D. with urea/O.D. without urea treatment]
× 100) (17).
Flow Cytometry Characterization of
Immune Responses
Single-cell suspensions of spleen or lymph nodes (LN) from
vaccinated, vaccinated/infected, non-vaccinated/infected, and
non-vaccinated/non-infected mice were prepared by standard
methods. Splenic and LN cell counts in vaccinated and control
mice are presented in Table S1. Splenocytes or LN cells (105
cells/100 µl color-free RPMI) were used immediately for flow
cytometry. In some experiments, splenocytes were in vitro
stimulated with TcL (25-µg/ml) at 37◦C, 5% CO2 for 48 h.
The un-stimulated and in vitro- stimulated cells were washed
in staining buffer (2% BSA/0.02% sodium azide in PBS) and
incubated for 15min with Fc Block (anti-CD16/CD32; BD
Pharmingen). Cells were then incubated for 30min at 4◦C
in dark with the fluorochrome-conjugated antibodies, washed
twice in PBS, fixed in 2% paraformaldehyde, and washed again.
Fluorescent cells were visualized by using a FACS-Calibur Cell
Analyzer (BD Biosciences), acquiring >20,000 events in a live
gate, and further analyzed by using FlowJo software (version
7.6.5, Tree-Star, San Carlo, CA) (22).
For the measurement of intracellular cytokines and immune
cell activation markers, splenocytes were stimulated as above
except that brefeldin A (10-µg/ml, Sigma) ormonensin (5µg/ml)
(BD Pharmingen) was added for the final 6 h of culture to block
protein secretion. Cells were then labeled with antibodies for
surface markers, fixed with 2% paraformaldehyde, re-suspended
in 100-µl permeabilization buffer (0.1% saponin/1% FBS in PBS),
and utilized for intracellular staining of cytokines or specific
markers. Samples were analyzed by flow cytometry as above. In
all experiments, unstained cells and cells stained with isotype-
matched IgGs and FMO were used as controls (13, 22).
All antibodies used for flow cytometry in this study are listed
in Table S2. Briefly, to profile the antigen presenting cells, splenic
and LN cells of all vaccinated and control groups before and
challenge infection were first gated for Ly6GloCD11c+ dendritic
cells (DC) and Ly6GloLy6C+CD11b+ monocytes/macrophages
(Mϕ). Each of the cell populations were further analyzed
by flow cytometry for the expression of CD209 (DC-SIGN)
C-type lectin receptor that recognizes PAMPs and activates
phagocytosis and/or antigen presentation, CD205 that is involved
in internalization, processing and presentation of antigens,
MHCI/MHCII molecules that bind to peptide fragments from
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FIGURE 1 | T. cruzi-specific antibody response in vaccinated mice. (A) Schematic of experimental plan is shown. C57BL/6 female mice were immunized with six
different compositions of vaccines as described in Materials and Methods. Mice were immunized with dose 1 at day 0, dose 2 at day 21, and on day 42 euthanized to
examine the vaccine-induced responses or challenged with Tc and then euthanized at day 63 to study the significance of vaccine in providing protection from
infection. Vaccines (per dose) were constituted with 25-µg each of pCDNA3.TcG2 and pCDNA3.TcG4 plasmid DNA (intramuscular) and/or 1 × 108 T. rangeli fixed
with 0.1% glutaraldehyde (fTr) with or without 5-µg Quil A (QA, subcutaneous). (B–G) T. cruzi-specific IgG (B), IgG1 (E), IgG2a (F), and IgG2b (G) antibodies in sera
samples were measured by an ELISA. The vaccine-induced IgGs specificity for T. cruzi was determined after pre-adsorbing the sera samples with T. rangeli soluble
lysate (C) and avidity of vaccine induced IgGs was calculated as [O.D. with urea/O.D. without urea treatment] × 100 (D). Sera samples from non-vaccinated or
infected mice were used as negative and positive controls, respectively. Data (mean ± SD) are representative of two independent experiments (n = 4 mice per group
per experiment, duplicate observations per sample), and significance is presented as * (none vs. vaccinated) or ∧ (comparison among vaccinated groups). The
p-values of <0.05, <0.01, and p < 0.001 are annotated with one, two, and three symbols, respectively.
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pathogens and present to the T cells, and CD80 that is the
ligand for CD28 and CTLA4 and provides co-stimulatory
signal for adaptive T cell response. The splenic CD11b+ Mϕ
cell subsets were also analyzed for intracellular expression of
markers of classical/proinflammatory (IL-1βhi and TNF-αhi) and
alternative/immunomodulatory (CD200+, CD206+) functional
phenotype after in vitro stimulation with TcL (25-µg/mL) for
48 h (18).
To evaluate the T cell profile, splenocytes from vaccinated,
vaccinated/infected, and control groups were in vitro stimulated
with TcL (25-µg/mL) for 48 h. Splenic CD3+ lymphocytes were
gated for CD4+ and CD8+ T cells. Each of the T cell subsets
were further analyzed for the expression of CD69 the early
activation marker of lymphocyte proliferation, CD11a (ITGAL)
that along with CD18 forms lymphocyte function-associated
antigen 1 (LFA-1) and binds with ICAMs to facilitate intercellular
adhesion of leukocytes, CD95 (Fas) / CD95L (FasL) involved
in immune elimination of infected cells, CD44 and CD62L
molecules to distinguish naïve (CD62LhiCD44lo), effector
(CD62LloCD44hi), and central memory (CD62LhiCD44hi)
phenotypes, and intracellular production of Th1 cytokines
(IFN-γ, TNF-α). The CD4+T cells were also examined for the
surface expression of CD25 and FoxP3 to profile the splenic T
regulatory cells. The CD8+T cells were also analyzed for the
intracellular expression of perforin and CD107a that are markers
of cytolytic activity (10, 11).
Histology and Tissue Parasite Burden
For histological studies, heart and skeletal muscle tissue sections
from vaccinated/infected and non-vaccinated/infected mice
were fixed in 10% buffered formalin for 24 h, dehydrated in
absolute alcohol, cleared in xylene, and embedded in paraffin.
Paraffin-embedded 5-micron tissue-sections were stained with
hematoxylin and eosin (H&E) and evaluated by light microscopy.
Heart and skeletal muscle tissue slides (three mice per group, at
least two slides per tissue, 10 microscopic fields per slide) were
analyzed by light microscopy, and the presence of inflammatory
cells was scored as (0)–absent/none, (1)–focal or mild with ≤1
foci, (2)–moderate with ≥2 inflammatory foci, (3)–extensive
with generalized coalescing of inflammatory foci or disseminated
inflammation (4)–severe with diffused inflammation, interstitial
edema, and loss of tissue integrity (23).
To examine the parasite burden, heart and skeletal
muscles tissues (10mg) from vaccinated/infected and non-
vaccinated/infected mice were subjected to proteinase K lysis,
and total DNA was purified by phenol/chloroform extraction
and ethanol precipitation. A real-time quantitative PCR was
performed on an iCycler thermal cycler with SYBR Green
Supermix (Bio-Rad), 50 ng of total DNA, and oligonucleotides
specific for Tc18SrDNA (forward, 5′- TTTTGGGCAACAGCA
GGTCT-3′; reverse, 5′- CTGCGCCTACGAGACATTCC-3′;
amplicon size: 199 bp) and murine GAPDH (forward, 5′-AACT
TTGGCATTGTGGAAGG-3′; reverse, 5′-ACACATTGGGGGT
AGGAACA-3′; amplicon size: 223 bp). The threshold cycle (CT)
values for Tc18SrDNA were normalized to GAPDH reference
cDNA. The relative parasite burden (i.e., Tc18SrDNA level)
was calculated by following the 2−11Ct, where 1Ct represents
the CT (sample)—Ct (GAPDH) and 11Ct represents 1Ct
(sample)—1Ct (no treatment control).
Statistical Analysis
Data are expressed as mean ± SD (n = 4/group/experiment,
minimum of duplicate observations per experiment). Data were
analyzed by the Student’s t-test (comparison of 2 groups) and
1-way analysis of variance (ANOVA) with Tukey’s post-hoc test
(comparison of multiple groups) by using an SPSS (version
14.0, SPSS Inc, Chicago, Illinois) or Graph Pad InStat ver.3
software. Significance is presented as ∗ (vaccinated vs. non-
vaccinated or vaccinated/infected vs. non-vaccinated/infected)
and ∧ (comparison of vaccinated groups) and p-values of
<0.05, <0.01, and 0.001 are annotated by one, two, or three
symbols, respectively.
RESULTS
Elicitation of Antibody Response and
Immune Cell Expansion in Mice Immunized
With DNA Vaccine (± fTr)
We first monitored if fTr, delivered as an adjuvant or as an
antigen in prime-boost approach, modulates the TcG2/TcG4
DNA vaccine—induced antibody response in mice. For this,
sera samples were obtained at 21 days after the 2nd vaccine
dose, and analyzed by an ELISA. Mice immunized/boosted
with TcG2/TcG4 (±QA, gp1, and gp3) exhibited no detectable
levels of Tc-specific antibodies (Figures 1B,C). In comparison,
all other vaccinated groups of mice that received fTr (±QA)
as adjuvant or booster exhibited detectable, though variable,
levels of Tc-specific IgGs with 25–51% avidity for Tc antigens
(Figures 1B,C). Including fTr as an adjuvant with TcG2/TcG4
vaccine (gp2) elicited maximal levels of Tc-specific IgGs
(∗p < 0.001) and addition of QA suppressed the fTr-induced
IgG (compare gp2 vs. gp4, ∧p < 0.001) (Figures 1B,C).
Interestingly, avidity of fTr induced antibodies for Tc antigens
was minimal among all vaccinated groups (compare gp2
with other groups, Figure 1D). Likewise, TcG2/TcG4 vaccine
adjuvanted with fTr also resulted in maximal levels of Tc-
specific IgG sub-types (IgG1, IgG2a, and IgG2b) (gp2 vs. all
other groups, ∗p < 0.01) while co-delivery of QA had a
suppressive effect on Tc-specific IgG subtypes stimulated by
TcG2/TcG4 vaccine adjuvanted with fTr (∧p < 0.001, compare
gp2 and gp4) or boosted with fTr (∧p < 0.05, compare gp5 and
gp6) (Figures 1E–G).
Tr-specific IgGs constituted of IgG1, IgG2a, and IgG2b
subtypes were also detected in mice that received fTr as an
adjuvant with TcG2/TcG4 DNA or as a booster vaccine, and
maximal Tr-specific antibodies were measured in sera of mice
given fTr as an adjuvant with TcG2/TcG4 DNA vaccine (group
2 vs. control, ∗p < 0.001, Figures S1A–D). Low levels of Tr-
reactive IgGs were also observed in mice infected with T. cruzi
(Figure S1B). Normal mice and mice injected with vector only
exhibited no Tc- and Tr-specific antibody response. Together,
the results presented in Figure 1 and Figure S1 suggest that (a)
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TcG2/TcG4 DNA vaccine induced low levels of Tc- and antigen-
specific antibodies, (b) co-delivery of fTr as an adjuvant elicited
maximal levels of Tc- as well as Tr-reactive IgGs with minimal
avidity for Tc antigens, and (c) addition of QA with fTr had
an overall suppressive effect on antibody responses induced in
vaccinated mice.
We evaluated the effect of vaccine compositions on the
expansion of splenic and lymph node (LN) cells in mice. With
respect to splenic cells, the overall frequency of splenocytes
(range: 80–193-million cells) was increased by 62–141% in
vaccinated (vs. control) mice (Table S1). Mice that received
booster dose of TcG2/TcG4, fTr, or fTr+QA exhibited maximal
expansion of splenocytes post-vaccination, while mice receiving
TcG2/TcG4 adjuvanted with fTr, QA or fTr+QA exhibited
minimal expansion of splenic immune cells (gp1, gp5, gp6,
Table S1). With respect to lymph nodes, we noted up to 52%
expansion of LN cells (range: 144-220-million cells) in vaccinated
mice, and maximal expansion was noted in mice immunized
with TcG2/TcG4 and boosted with fTr or fTr+QA (gp5 and gp6,
Table S1). Based on the observations that fTr, QA, and fTr+QA
adjuvants (gp2, gp3, gp4) did not enhance the TcG2/TcG4-
induced expansion of splenic and LN cells (Table S1) as well as
high avidity antibody responses (Figure 1), we excluded the gp2,
gp3, and gp4 from further studies.
Expansion of DNA Vaccine (± fTr)–Induced
Antibody Response Upon
Challenge Infection
To examine if vaccine-induced IgGs expanded in response to
infection, mice were challenged with T. cruzi at 21 days’ pv, and
sera samples were obtained at 21 days’ pi (corresponds to acute
parasitemia phase). All mice challenged with Tc, irrespective
of the vaccination regimen, exhibited significant levels of Tc-,
TcG2-, and TcG4-specific IgGs (vs. normal controls, ∗p < 0.05,
Figures 2A–C). Booster immunization with fTr (±QA) slightly
enhanced the hosts’ capacity to respond to challenge infection
with expansion of Tc-specific antibodies than was observed
in TcG2/TcG4-immunized/infected mice (Figure 2A); however,
booster immunization with fTr (±QA) did not enhance
the TcG2- and TcG4-specific IgGs in DNA vaccinated mice
(Figures 2B,C, compare gp5 and gp6 with gp1). The maximal
levels of Tc- and antigen-specific IgGs were detected in infected
mice that did not receive any vaccine (vs. vaccinated/infected,
∧p< 0.05, Figures 2A,C).We alsomonitored theTc and antigen-
specific antibody sub-types in immunized mice post challenge
infection. Overall, all mice responded to challenge infection
with a significant increase in Tc- TcG2- and TcG4-specific
IgG1, IgG2a, and IgG2c antibody subtypes (vs. normal controls,
∗p< 0.01, Figures 2D–L). Maximal levels of Tc- and TcG2/TcG4-
specific antibody subtypes (IgG2a+IgG2c > IgG1) were detected
in non-vaccinated/infectedmice (vs. normal controls, ∗p< 0.001,
Figures 2D–L). Mice immunized with TcG2/TcG4 and boosted
with TcG2/TcG4 also exhibited a predominance of Tc and
antigen-specific IgG2a/2c (vs. IgG1) antibody sub-types post-
challenge infection (compare Figures 2G–L with Figures 2D–F).
Further, booster immunization with fTr (±QA) slightly,
but non-significantly, enhanced the Tc- and antigen-specific
antibody subtypes post-challenge infection than was observed in
TcG2/TcG4-immunized/infected mice (Figures 2D–L). Together
the results presented in Figure 2 suggest that (a) challenge
infection elicits a predominance of antigen- and parasite-specific
IgG2a/2c antibodies that are not enhanced by pre-immunization
with DNA vaccine; and (b) fTr (±QA) did not improve the
extent of antigen- and parasite-specific IgGs in TcG2/TcG4-
vaccinated mice.
DC Activation Profile in Vaccinated Mice
Before and After Challenge Infection
With Tc
The overall frequencies of DC (Ly6GloCD11c+, spleen: 4.4–
6.2%, LN: 0.97–1.7%) as well as of CD209+ (maturation
marker) and MHCI+ (antigen presentation marker) DC were
either not changed or slightly decreased in spleen and LN of
vaccinated (vs. non-vaccinated/control) mice (Figures 3A,B).
However, the splenic frequencies of CD205+, MHCII+ and
CD80+ DC, indicating an increase in antigen uptake, processing,
and presentation to CD4+T cells, were increased by >2-fold in
TcG2/TcG4 DNA vaccinated mice (all, ∗p < 0.01, Figure 3A).
An increase in antigen presenting capacity of LN DC was also
evidenced by ∼2-fold increase in the frequency of CD205+ and
MHCII+ DC in TcG2/TcG4 DNA vaccinated mice (∗p < 0.05,
Figure 3B). Importantly, boosting the TcG2/TcG4 DNA vaccine
with fTr (±QA) had none or suppressive effects on the splenic
and LN DC activation (Figures 3A,B).
Challenge infection with T. cruzi led to > 3-fold increase
in the frequency of CD11c+ DC and a comparable increase in
the frequency of CD205+ and CD80+ DC in the splenic and
LN compartment of mice that were immunized with TcG2/TcG4
DNA vaccine (compare Figures 3A,B with Figures 3C,D).
Boosting with fTr or ftr+QA had non-significant or suppressive
effects on TcG2/TcG4-induced DC activation post-challenge
infection, and frequencies of MHCI+ and MHCII+ DC were not
significantly changed in spleen and LN of vaccinated groups post-
infection (Figures 3C,D). Non-vaccinated/infected (vs. normal
control) mice exhibited an overall contraction of the splenic
and LN levels of Ly6GloCD11c+ DC, and the low number of
surviving DC primarily exhibited a MHCII+ phenotype in non-
vaccinated/infected mice (Figures 3C,D). Together, the results
presented in Figure 3 suggest that (a) TcG2/TcG4 DNA vaccine
induced DC depot was capable of responding to Tc infection
by increased proliferation and phenotypic (antigen uptake,
processing, and presentation to CD4+T cells) activation, and (b)
fTr booster was not useful in enhancing the DC response induced
by DNA vaccine in mice before or after challenge infection.
Mϕ Activation Profile in Vaccinated Mice
(± Tc)
The splenic and LN profile of Mϕ are presented in Figure 4 and
Figure S2. The overall percentages of Ly6GloLy6C+CD11b+ Mϕ
(range: 1.5–2.2% of total splenocytes) as well as of CD209+ and
MHCI+ Mϕs were either not changed or decreased in the splenic
compartment of vaccinated mice (vs. non-vaccinated controls,
Frontiers in Immunology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 1456
Gupta et al. Vaccine Testing Against T. cruzi
FIGURE 2 | Antibody response in vaccinated mice after challenge infection. C57BL/6 female mice were immunized with subunit vaccine (pCDNA3.1 encoding TcG2
and TcG4) at day 0, boosted with subunit vaccine, fTr, or fTr+QA at day 21, and challenged with T. cruzi (10,000 parasites per mouse, intraperitoneal) at day 42. Mice
were euthanized at day 63 (i.e., 21 days’ post challenge infection). Sera samples were analyzed by an ELISA to evaluate the IgG (A–C), IgG1 (D–F), IgG2a (G–I), and
IgG2c (J–L) levels captured with T. cruzi lysate (A,D,G,J) and recombinant TcG2 (B,E,H,K), and TcG4 (C,F,I,L) antigens. Sera samples from normal and infected mice
were used as controls. Data (mean ± SD) are representative of duplicate observations per sample (n = 4 mice per group per experiment), and significance is
annotated as * (none vs. vaccinated or infected vs. vaccinated/infected) and ∧ (comparison of vaccinated groups) (*,∧p < 0.05, **,∧∧p < 0.01, and ***p < 0.001).
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FIGURE 3 | Antigen presenting capacity of dendritic cells (DC) in vaccinated mice (± T. cruzi). Mice were vaccinated and challenged with T. cruzi trypomastigotes
(10,000 parasites/mouse), as in Figures 1, 2. Mice were euthanized at 21 days’ post-vaccination (pv) or 21 days’ post-infection (pi). Single cell suspensions of spleen
(A,C) and lymph nodes (B,D) of vaccinated (A,B) and vaccinated/infected (C,D) mice were labeled with fluorochrome-conjugated antibodies and analyzed by flow
cytometry. Bar graphs show ex vivo percentage of Ly6GloCD11c+ splenic DC (SDC) and lymph node DC (LNDC) subsets that expressed markers of maturation
(CD209+), stimulation (CD80+), antigen uptake (CD205+), and antigen presentation (MHCI+, MHCII+) in vaccinated and vaccinated/infected mice. SDC and LNDC
from non-vaccinated/non-infected (none) and non-vaccinated/infected mice were used as controls. Data are presented as mean ± SD and representative of duplicate
observations per sample (n = 4 mice per group per experiment). Significance is annotated as * (none vs. vaccinated or infected vs. vaccinated/infected) and ∧
(comparison of vaccinated groups) (*,∧p < 0.05, **,∧∧p < 0.01, and ***,∧∧∧p < 0.001).
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Figure 4A). Mice immunized with TcG2/TcG4 (gp2) exhibited
60%, 170%, and 1350% increase in the frequencies of CD205+,
MHCII+, and CD80+ Mϕ, indicating an increase in antigen
uptake, processing, and presentation, respectively, to CD4+T
cells (all, ∗∗p < 0.01, Figure 4A), while booster immunization
with fTr or fTr+QA (gp5 and gp6) resulted in increased
expression of CD205 only (vs. normal controls, Figure 4A).
Upon challenge infection, TcG2/TcG4 vaccinated mice exhibited
a further 3-4-fold increase in splenic frequency of Mϕ that
were primarily CD205+ (compare Figures 4A,B). Including fTr
or fTr+QA booster dose had either no effects or suppressive
effects on CD209+, MHCI+, and MHCII+ Mϕ responses after
TcG2/TcG4 vaccination and challenge infection (∧p < 0.05,
Figures 4A,B), and CD80+ Mϕ were significantly enhanced by
fTr+QAbooster immunization in challengedmice, suggesting an
increase in B7-1 costimulatory signal for T cell activation.
Functional analysis of splenic Mϕ after in vitro stimulation
with Tc lysate for 48 h showed 5-9-fold increase in the
frequencies of proinflammatory (CD200lo, IL-1βhi, and TNF-
αhi) and immunomodulatory (CD200hi and TNF-αlo) CD11b+
Mϕ in TcG2/TcG4-vaccinated mice (vs. normal controls, all,
∗∗∗p < 0.05 Figures 4C,D). Splenic Mϕ of vaccinated/infected
mice responded to in vitro stimulation with Tc lysate with a
further >2-fold increase in the splenic expansion of CD200hi
and TNF-αhi Mϕ (compare Figures 4C,D with Figures 4E,F).
Except for an increase in CD206hiCD11b+ Mϕ population
(Figure 4C), inclusion of fTr booster had non-significant effects
on TcG2/TcG4-induced Mϕ activation before or after challenge
infection, and co-delivery of QA had an overall suppressive effect
on the splenic CD11b+ Mϕ in vaccinated mice (Figures 4C–F).
Non-vaccinated mice exhibited an increase in CD206lo Mϕ sub-
population post-challenge infection (Figure 4F).
In the LN compartment, non-significant changes or a decline
in the percentages of CD205+, CD209+, MHCI+ MHCII+, and
CD80+ Mϕ were detected in TcG2/TcG4-vaccinated (vs. control)
mice (Figure S2A). Inclusion of fTr or fTr+QA booster had an
overall suppressive effect on all of the TcG2/TcG4-induced sub-
populations of LN Mϕ, except that fTr+QA booster enhanced
the frequency of MHCII+CD11b+ Mϕ in DNA-vaccinated
mice (Figure S2A ). Further, challenge infection resulted in no
increase in the overall percentages of CD11b+ LN Mϕ in any of
the vaccinated groups (Figure S2B). Yet, a substantial phenotypic
activation, evidenced by an increase in the frequency of CD205+,
MHCI+, and CD80+ Mϕ, was noted in LN of TcG2/TcG4
vaccinated/infected mice (compare Figures S2A,B). Inclusion of
fTr (±QA) booster increased the CD205 and CD80 expression
and had no significant effect on the CD209 and MHCII
expression than that noted in TcG2/TcG4 immunized mice post-
challenge infection (Figure S2B). Non-vaccinated/infected (vs.
normal control) mice continued to exhibit a predominance
of antigen presenting Mϕ (MHCII+) in the LN compartment
(Figure S2B). Together, the results presented in Figure 4 and
Figure S2 suggest that (a) TcG2/TcG4 DNA vaccine induced
Mϕ depot was capable of responding to T. cruzi infection by
increased proliferation, and proinflammatory activation (antigen
uptake, processing, and presentation to CD4+ T cells; production
of IL-1β+ and TNF-α cytokines), and (b) fTr based booster
immunization had minimal-to-none effects in further enhancing
the Mϕ response induced by DNA vaccine in mice before or after
challenge infection.
CD4+T Cell Profile in Vaccinated Mice
(± Tc)
Next, we examined if the TcG2/TcG4-induced activation of
antigen presenting cells modulate the splenic CD4+T cell
responses in mice after immunization and challenge infection.
For this, splenocytes from vaccinated, vaccinated/infected, and
control mice were in vitro stimulated with Tc lysate, CD3+
lymphocytes were gated for CD4+T and CD8+T cell subsets, and
each of the T cell subsets were further analyzed by flow cytometry.
Vaccinated (vs. normal control) mice exhibited a significant
increase in splenic population of CD4+T cells (range: 9.76–
18.8% of total) and CD4+TNF-α+T cells (range: 2.1–7.4% of
CD4+T cells), respectively (all, ∗p < 0.05, Figure 5A). Maximal
expansion in CD4+T cells was noted in mice immunized with
TcG2/TcG4 and boosted with fTr±QA. No significant differences
in the expression of other markers of CD4+T cell activation
(CD69, CD95, CD95L) were noted in any of the vaccinated (vs.
normal control) groups (Figure 5B). Interestingly, fTr booster
skewed the CD4+T cells from effector (CD62LloCD44hi) to
central memory (CD62LloCD44hi) phenotype and addition of
QA reversed this effect in vaccinated mice (Figure 5C).
Upon challenge infection, CD4+T cells constituted 7.4–
12.6% of the total splenocytes, and a large proportion of the
CD4+T cells exhibited a CD69+/CD11a+ phenotype (range:
7.7–22%) indicative of T cell recruitment and early activation
(Figure 4E). Importantly, CD4+T cells in vaccinated/infected
(vs. non-vaccinated/infected) mice exhibited >10-fold and 2-
6-fold increase in Th1 cytokine (TNF-α) production and
Fas/FasL (CD95+/CD95L+) expression, respectively (∗p < 0.01,
Figures 5E,F), that are required to support CD8+T cells in
eliminating intracellular infection. Moreover, up to 24% of the
naïve CD4+T cells also differentiated to induced T regulatory
(iTreg) phenotype (CD25+FoxP3+) in vaccinated mice before
and challenge infection (∗p < 0.01, Figures 5D,H). While
adjuvanting with fTr±QA had no effect (data not shown),
delivery of fTr±QA as booster dose substantially increased
the expansion of CD4+T cells and iTreg population when
compared to that noted in mice immunized with TcG2/TcG4
only (all, ∧p < 0.05, Figures 5A,D). However, fTr±QA booster
did not enhance the DNA vaccine induced CD4+T cell
responses after challenge infection (Figures 5E–H). In non-
vaccinated/infected (vs. normal control) mice, the CD4+T
cells exhibited an increase in the expression of CD11a and
CD69, but maintained a predominance of naïve (CD62Lhi) or
central memory (CD62LhiCD44hi) phenotype (Figures 5E–G).
Together, the results presented in Figure 5 suggest that (a)
TcG2/TcG4DNA vaccine induced CD4+T cells acquired the Th1
phenotype evidenced by TNF-α production and expression of
markers that orchestrate adaptive immunity to kill intracellular
pathogen; (b) a fraction of the vaccine-induced CD4+T cells
acquired iTreg phenotype to potentially avert the over-reactivity
of the immune responses and prevent self-tissue injury; and
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FIGURE 4 | Antigen presenting capacity and functional profile of splenic macrophages (Mϕ) in vaccinated mice (± T. cruzi). Mice were vaccinated and challenged with
T. cruzi trypomastigotes as in Figures 1, 2. (A,B) Splenocytes were labeled with fluorochrome-conjugated antibodies and analyzed by flow cytometry. Bar graphs
show ex vivo percentages of the splenic Ly6GloCD11b+ Mϕ that exhibited surface expression of markers of maturation, antigen uptake, and antigen presentation
(CD205+, CD209+, MHCI+, MHCII+, CD80+) in vaccinated (A) and vaccinated/infected (B) mice. (C–F) Splenic cells from vaccinated (C,D) and vaccinated/infected
(E,F) mice were in vitro stimulated for 48 h in the presence of soluble T. cruzi lysate (TcL), and then labeled with fluorochrome-conjugated antibodies. Shown are the
mean percentages of CD11b+ Mϕ that responded to TcL stimulation with expression of markers of classical/proinflammatory (IL-1βhi, TNF-αhi) and
alternative/immunomodulatory (CD200hi, CD206hi) phenotype. Splenic cells from non-vaccinated/non-infected and non-vaccinated/infected mice were used as
controls. Data (mean ± SD) are representative of two independent experiments (n = 3 mice per group per experiment, duplicate observations per mouse), and
significance is annotated as *none vs. vaccinated or infected vs. vaccinated/infected, and ∧comparison of vaccinated groups (*,∧p < 0.05, **,∧∧p < 0.01, and
***,∧∧∧p < 0.001).
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FIGURE 5 | CD4+T cell functional profile in vaccinated mice (± T. cruzi). Mice were vaccinated and challenged with T. cruzi trypomastigotes as in Figures 1, 2.
Splenocytes from vaccinated (A–D) and vaccinated/infected (E–H) mice were in vitro stimulated for 48 h in the presence of soluble T. cruzi lysate, labeled with
(Continued)
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FIGURE 5 | fluorochrome-conjugated antibodies, and analyzed by flow cytometry. Shown are the percentages of PE+CD4+ splenic T cells exhibiting the expression
of markers of (A,E) recruitment (CD11a+, CD69+) and activation (TNF-α+); (B,F) cell death (CD95+, CD95L+); (C,G) effector/memory phenotype (CD62L+,
CD44+); and (D,H) T regulatory phenotype (CD25+ ± FoxP3+). Data (mean ± SD) are representative of two independent experiments (n = 3 mice per group per
experiment, duplicate observations per sample), and significance is annotated as *none vs. vaccinated or infected vs vaccinated/infected, and ∧comparison of
vaccinated groups (*,∧p < 0.05, **,∧∧p < 0.01, and ***,∧∧∧p < 0.001).
(c) including fTr booster immunization slightly shifted the
CD4+T cell response toward iTreg population in vaccinated
mice. In comparison, (d) non-vaccinated mice failed to respond
to challenge infection with a potent activation of Th1 CD4+T
cell response.
CD8+T Cell Function in Vaccinated Mice
(± Tc)
The splenic CD8+T cell response to vaccination and challenge
infection is presented in Figure 6. The overall CD8+T cell
population (range: 17.7–20.1% of total splenocytes) was only
slightly increased in vaccinated (vs. control) mice (Figure 6A).
Yet, the frequencies of CD8+T cells expressing the phenotypic
markers of early activation (CD69, 3.29–8.05% of CD8+T cells)
and cell migration/adhesion (CD11a: 0.69–2.78% of CD8+T
cells) were increased by 43–144% and 104–302%, respectively,
in vaccinated (vs. control) mice (∗p < 0.05, Figure 6A),
the maximal increase being noted in TcG2/TcG4 -immunized
mice. Flow cytometry also revealed that vaccination primed
type 1 immunity evidenced by a significant increase in the
frequency of IFN-γ+ (∼1.2% of total, up to 8-fold increase)
and TNF-α+ (3.2–7.5%, 0.5–2.5-fold increase) CD8+T cells with
a polyfunctional, cytolytic phenotype (Perforin+CD107+: 8.4–
27.5% of CD8+T cells, 1.7–7.8-fold increase; Perforin+TNF-
α+: 2.5–5.4% of CD8+T cells, 1.3–3.9-fold increase) when
compared to non-vaccinated controls (Figures 6A,B, p < 0.05).
The maximal increase in CD8+T cell frequency, activation,
and poly-functional phenotype was noted in mice immunized
with TcG2/TcG4 DNA vaccine only or boosted with fTr+QA.
Splenic CD8+T cells exhibited no changes in the expression
of other markers of activation (CD95/CD95L, Figure 6C). As
was noted for CD4+T cells, immunization with fTr booster
skewed the CD8+ T cells from effector (CD62LloCD44hi) toward
central memory (CD62LloCD44hi) phenotype and addition of
QA reversed this effect in vaccinated mice (Figure 6D).
Upon challenge infection, the overall splenic percentage
of CD8+T cells (range: 10.3–13%) contracted in vaccinated
mice, yet, CD8+T cells in vaccinated mice responded to
challenge infection with an increase in the expression of
phenotypic markers of T cell recruitment and early activation
(CD69: 14.3–18.3% of CD8+T cells, CD11a: 6.7–10.2% of
CD8+T cells, compare Figures 6A,E). Transport of integral
membrane proteins’ (CD107a and CD107b) to plasma
membrane, expression of perforin and granzyme or Fas/FasL
(CD95/CD95L), and release of IFN-γ and other cytokines
offer effector CD8+T cell function through direct killing of the
infected cells and/or pleiotropic effects that suppress intracellular
pathogen (19). The flow cytometry data showed that vaccinated
(vs. non-vaccinated) mice responded to challenge infection with
>8-fold increase in the frequency of Th1 cytokine producing
(IFN-γ: 3.9–5.1%, TNF-α: 3.5–5.2%) CD8+T cells (all, ∗p< 0.05,
Figure 6F). Further, the frequencies of CD8+T cells responding
to challenge infection with a polyfunctional, cytolytic activation
(Perforin+CD107+: 24–26.5%, Perforin+TNF-α+: 4.0–5.8%;
CD95+CD95L+: 3.6–6.6%) were significantly increased in
vaccinated/infected (vs. non-vaccinated/infected) mice (all,
∗p < 0.05, Figures 6E–G). The potent increase in CD8+T cell
frequency, activation, and functional phenotype noted in mice
immunized with TcG2/TcG4 DNA vaccine only was not boosted
when fTr±QA were added as adjuvant (data not shown) or as
a heterologous booster vaccine (Figure 6). The CD8+T cells of
non-vaccinated mice responded to challenge infection with an
increase in the markers of early activation (CD11a and CD69,
Figure 6E), and effector (CD62LloCD44hi) or central memory
(CD62LhiCD44hi) phenotype (Figure 6H) but failed to develop
polyfunctional cytolytic response (Figures 6E–G). Together, the
results presented in Figure 6 suggest that TcG2/TcG4 vaccine
elicited type 1 CD8+T cell activation. The vaccine-induced
CD8+T cells were polyfunctional, and, thus, had a potential to
act as cytolytic, effector T cells against T. cruzi. The heterologous
vaccination with fTr and QA had no clear additive effect in
enhancing the TcG2/TcG4 DNA vaccine induced Tc-specific
functional CD8+ T cell profile.
Vaccine Efficacy in Controlling Tissue
Pathology and T. cruzi Infection
Finally, we determined if fTr (±QA) booster immunization
enhanced the TcG2/TcG4 vaccine efficacy in controlling
inflammatory pathology associated with tissue parasite burden.
Histological studies revealed low level of infiltration of
inflammatory cells in the heart (Figures 7B–D, histological
score: 0–1) and skeletal muscle (Figures 7G–I, histological
score: 0–1) of all groups of vaccinated/infected mice. The extent
of inflammatory infiltrate in heart and skeletal muscle tissues
of non-vaccinated/infected mice (Figures 7E,J, histological
score: 2–4) was significantly higher than that detected in
tissues of vaccinated/infected mice. Extensive inflammatory
foci as well as diffused inflammation, interstitial edema, and
loss of tissue integrity were visible in all tissue sections of
non-vaccinated/infected mice (Figures 7E,J). In comparison,
tissue sections from normal mice showed no inflammatory
infiltrate (Figures 7A,F).
The control of tissue parasite burden by immunization
was validated by real time qPCR. All vaccinated/infected mice
exhibited non-detectable levels of Tc18SrDNA in the heart tissue
(Figure 7K). The skeletal muscle levels of Tc18SrDNA were also
barely detectable in vaccinated mice (Figure 7L). A slightly better
control of parasite burden in the skeletal muscle was noted in
mice vaccinated with TcG2/TcG4 DNA followed by fTr+QA
than in mice given other vaccine compositions (Figure 7L). In
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FIGURE 6 | CD8+T cell functional profile in vaccinated mice (± T. cruzi). Mice were vaccinated and challenged with T. cruzi as in Figures 1, 2. Splenocytes from
vaccinated (A–D) and vaccinated/infected (E–H) mice were in vitro stimulated for 48 h in the presence of Tc antigenic lysate, and then labeled with
fluorochrome-conjugated antibodies. The FITC+CD8+T cells were analyzed by flow cytometry. Shown are the mean percentages of (A,E) CD8+T cells expressing
adhesion and migration markers (CD11a+, CD69+) and type 1 cytokines (IFN-γ and TNF-α) production; (B,F) poly-functional CD8+T cells that exhibited several
markers of cytolytic activity (perforin+, CD107a+, TNF-α+, and IFN-γ+); (C,D) CD8+T cells with expression of cell death markers (CD95+, CD95L+); and (C,G)
CD8+T cells expressing effector/memory markers (CD44+, CD62L+). Data (mean ± SD) are representative of two independent experiments (n = 3 mice per group
per experiment, duplicate observations per sample). Significance is annotated as *none vs. vaccinated or infected vs vaccinated/infected, and ∧comparison of
vaccinated groups (*,∧p < 0.05, **,∧∧p < 0.01, and ***,∧∧∧p < 0.001).
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FIGURE 7 | Tissue inflammation and parasite burden in vaccinated mice post-challenge infection. Mice were vaccinated as in Figure 1, challenged with T. cruzi at 21
days’ post-vaccination and euthanized at 21 days post-infection. (A–J) Paraffin-embedded left ventricular heart (A–E) and skeletal muscle (F–J) tissue sections (5µM)
were examined by hematoxylin/eosin staining (blue: nuclear; pink: muscle/cytoplasm). Shown are representative H&E images of tissue sections from
vaccinated/infected and non-vaccinated/infected mice. Non-treated/non-infected mice were used as controls. (K,L) Total DNA was isolated from heart (K) and
skeletal muscle (L) tissue sections and submitted to real-time qPCR amplification of Tc18SrDNA sequence (normalized to murine GAPDH). Data (mean ± SD) are
representative of two independent experiments (n = 4 mice per group per experiment, triplicate observations per sample). Significance is annotated as *none vs.
vaccinated or infected vs vaccinated/infected, and ∧comparison of vaccinated groups (*,∧p < 0.05, **,∧∧p < 0.01, and ***,∧∧∧p < 0.001).
comparison, non-vaccinated/infected mice exhibited >10-fold
higher levels Tc18SrDNA in the myocardial and skeletal muscle
tissues post-challenge infection (∧p < 0.001, Figures 7K,L).
Together, these results suggest that TcG2/TcG4-based DNA
vaccine is highly effective in reducing the acute tissue parasite
burden and associated inflammatory pathology, and boosting the
TcG2/TcG4-based immunity with fTr (±QA) provides minimal
benefits in enhancing the vaccine efficacy against acute T. cruzi
persistence and tissue injury in mice.
DISCUSSION
In this study, we have conducted detailed immunological
analysis to determine how a homologous DNA-prime/DNA-
boost vaccine provides protection from T. cruzi infection and
examined if the DNA vaccine’s efficacy can be complemented
with T. rangeli as an adjuvant or antigen.
Subunit vaccines are the safest form of vaccine (17, 18). Pre-
clinical and clinical trials have demonstrated significant efficacy
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of subunit vaccines, e.g., THYB-03 (tuberculosis), influvac
(influenza), rts,s/AS01 (malaria), gD2gB2-MF59 (HSV2), and
RV144 (HIV) (20). In the context of Chagas disease, several
candidate antigens (e.g., ASP2, CRP, cruzipain, GP90, GP82,
GP56, Tc24, Tc52) have been tested as subunit vaccine, delivered
in the form of DNA, recombinant protein, or a host of viral and
bacterial expression vectors, in small animal models [reviewed
in Padilla et al. (19) and Zak and Aderem (20)]. However,
in a majority of the studies, the selected vaccine candidates
were chosen based on the preferences or biases of the research
teams and investigators. To prevent the investigator bias in
vaccine design, we developed a computational/bioinformatic
algorithm for screening the Tc sequence database for the vaccine
candidates (4). We identified 11 potential candidates that were
submitted to rigorous analysis for eliciting immunity against Tc
(5, 8, 21, 24). Eventually, we narrowed down to TcG1, TcG2,
and TcG4 candidates that exhibited relevant characteristics as
vaccine candidates. These antigens were (1) highly conserved in
clinically relevant Tc isolates (4), (2) expressed (mRNA/protein)
in trypomastigotes and amastigotes (mammalian stages) of Tc
(4), and (3) recognized by IgGs and type 1 CD8+T cells
in experimentally or naturally infected mice (5), dogs (6),
and humans (7). In a series of studies, we have tested the
vaccine potential of TcG1, TcG2, and TcG4 through the use of
recombinant eukaryotic plasmid DNA or viral vectors or as a
recombinant protein, in eliciting resistance to Tc infection (7–11,
16, 18). The homologous DNA-prime/DNA-boost was simplest
in composition, and most cost-effective and field-ready, and
therefore tested in several compositions (individual candidate
antigens, co-delivery of antigenic candidates, different doses and
time-intervals, with or without cytokine adjuvants etc.) (4, 5, 23,
25). We found that each of the three candidates elicit antigen-
specific IgG and CD8+T cell responses and co-delivery of the
vaccine candidates elicited additive immune responses (8). The
TcG1 candidate was least immunogenic; it stimulated antibody
and T cell responses only when it was delivered with IL-12 and
GM-CSF adjuvants, and, therefore, it was removed from the later
formulations (11). Our published studies discussed above and
the present results also suggest that two-dose vaccine delivered
at 21-day interval is the most efficacious approach for eliciting
anti-parasite protective immune responses.
Our choice of fixed Tr as an adjuvant and booster was based
on the literature findings that show that Tr shares significant
antigenic homology with T. cruzi (26, 27); Tr infects triatomines
and mammals but does not induce disease in humans (22, 28),
and Tr does not circulate in some of the endemic countries
(29). Studies in rodents and dogs have shown that exposure
to T. rangeli or use of heat or chemically attenuated Tr elicits
antibodies that are reactive against Tc antigens, and antibody
response was associated with a degree of resistance to infection
with T. cruzi (30–32). It is also proposed that Tr can adjuvant the
innate and adaptive immunity against Tc infection, though this is
not experimentally shown.
Monocytes (Mo), Mϕ, and DCs are the mononuclear
phagocytic cells that together constitute monocyte phagocyte
system (MPS) (33). Mo/Mϕ cells elicit the primary immune
defense to invadingTc by proinflammatory cytokines’ expression;
and superoxide and nitric oxide (NO) production by the NADPH
oxidase (NOX2) and inducible nitric oxide synthase (iNOS)
enzymes, respectively (34–36). Along with the cytokines and
other mediators they produce, Mϕ and DC also serve an
important function of antigen presentation to adaptive immune
system, and thus strongly influence the magnitude and quality
of the vaccine induced protection. Our characterization of DC
and Mϕ responses in this study showed that TcG2/TcG4 DNA
immunization increased the frequencies of splenic and LN
DCs and Mϕ expressing markers of antigen uptake, processing,
and presentation (e.g., CD205, CD209, MHCII, CD80). The
DNA vaccine induced Mϕ, despite the immunomodulatory
(CD200hi) phenotype, exhibited proinflammatory functional
activation (TNFαhi/IL-1βhi) that was further amplified upon
in vitro stimulation with Tc lysate as well as upon challenge
infection. The observations that the TcG2/TcG4-induced innate
immune cells expanded both the antigen presentation and
functional profile in response to 2nd stimulation (Figures 3, 4)
suggest that DNA vaccine-induced innate immune cells retained
memory of Tc-specific antigen exposure. Indeed, there is growing
appreciation for Mϕs’ contribution to innate immune memory; a
recent study showed Mϕ memory to S. aureus was tissue specific
and transferable between individual animals (37). Also referred as
trained immunity, innate immunememory favors the production
and release of proinflammatory cytokines (e.g., TNF-α, IL-6, and
IL-1β) (38), as we have noted in vaccinated/challenged mice, and
it is also defined by metabolic and epigenetic hallmarks. Recent
studies have shown that metabolic reprogramming through
a shift from oxidative phosphorylation to aerobic glycolysis
mediated by Akt/mTOR/HIF-1α pathway is a key mechanism
for trained immunity (39); while glycolysis, glutaminolysis,
and cholesterol synthesis pathways in Mo/Mϕ were suggested
to support the epigenetic wiring and induction of improved
innate immunity (39, 40). Further studies will be needed
to mechanistically demonstrate if TcG2/TcG4 DNA vaccine
promoted the metabolic and epigenetic shifts, and evaluate the
longevity of the trained innate immunity and its effects on T cell
responses. Yet, our results allow us to surmise that the subunit
vaccine design harnessed both the effector response of innate
immune cells as well as activation state to enhance adaptive T
cell response to the antigens.
Quality and quantity of T cell response, and their
cytokine polyfunctionality are critical factors in defining
the protective efficacy of vaccine(s) against intracellular
pathogens. Immunodominant peptides binding stably to MHC
class II on the surface of APCs enhance the recruitment and
proliferation of effector CD4+ T cells, and secretion of IFN-
γ/TNF-α and chemokines by activated APCs and CD4+T cells
enhance the CD8+T cells’ accumulation (41). Of a number
of immune mediators produced by T cells, IFN-γ and TNF-α
play a major role in parasite clearance (10, 12), and production
of these cytokines together leads to enhanced killing than
either cytokines alone. Additionally, CD8+ (and to some
degree CD4+) T cells mediate cytolytic activity through the
release of perforin/granzymes (10). We have noted that DNA
immunization of mice enhanced the frequency of Th1 effector
CD4+T cells and poly-functional, cytotoxic CD8+T cells that
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had the capability to respond to challenge infection with
further expansion. The control of tissue parasite burden in
immunized mice by >90% suggest that the vaccine induced T
cells were highly effective in killing the intracellular pathogen
and consequently pathological tissue inflammation was also
controlled. CD4+ T cells also support immunoglobulin switch
and affinity maturation of B cells that enhances the production of
neutralizing antibodies; however, we did not notice an increase
in quality or quantity of antibody production in vaccinated mice,
thus, suggesting that B cell response was not a major feature
of the current vaccine design. Another essential feature of the
T cells is the type and homing properties of the memory T
cell subsets. Whether the current DNA vaccine will provoke
long-term/sustained memory T cell response remains to be seen
in future studies.
Our results in this study support the existing literature and
clearly demonstrate that use of fTr as an adjuvant to subunit
DNA vaccine or as an antigen in a booster vaccine dose elicits
Tc-reactive antibodies that are not elicited by DNA vaccine only.
However, fTr did not improve the host outcomes evidenced
by the findings that the subunit DNA vaccine delivered by a
homologous prime/boost approach was capable of providing
>90% control of tissue parasite burden, and inclusion of fTr
in a heterologous prime/boost approach did not significantly
enhance the efficacy of the DNA vaccine. Further, the inclusion
of fTr complicates the efficacy of treatment with anti-parasite
drugs or vaccines, as seroconversion is routinely taken as a
measure of parasite clearance, and presence of fTr-induced
antibodies can hinder the development and efficacy testing of
the new drugs and vaccines. Thus, considering the hurdle of
facilities, resources and costs associated with the production
of fTr, we surmise that inclusion of fTr in subunit vaccine
is not needed. These results also provide an explanation for
why the first generation of vaccines prepared from the T.
cruzi parasites (attenuated, killed, fractionated etc.) were not
rigorously followed for designing of a commercially viable
Chagas vaccine.
With the advancement of CRISPR and other technologies
to knockdown genes in trypanosomes, the interest in the
development of genetically attenuated live T. cruzi vaccine
has rekindled (42, 43). The proponents of the live attenuated
vaccine believe that such a vaccine will mimic the natural course
of infection and provide an appropriate microenvironment
of antigen processing and presentation, create a subclinical
infection, provide a full-spectrum of antigenic epitopes, and
ensure antigen persistence for stimulation of long-lasting
immunological responses (44). Yet, other investigators are
concerned that an attenuated live vaccine may trigger a
full-blown infection and disease in the immunocompromised
individuals. Further, a live vaccine, even if protective against
one lineage of T. cruzi, may not be efficacious in providing
protection from infection from other five lineages of T. cruzi.
Indeed, experimental studies have shown that mice infected with
T. cruzi and cleared of parasite by treatment with anti-parasite
drugs are not protected from re-challenge infection (45). Thus,
the concerns in the use of Tr- or Tc-based attenuated vaccines
appear to outweigh the benefits offered by whole organism
vaccine in the context of Chagas disease, though this remains to
be experimentally proven.
In summary, we have demonstrated that a DNA-prime/DNA-
boost vaccine using relatively simple immunogens provides
protection from challenge infection. The TcG2/TcG4 DNA
vaccine (a) stimulated pro-inflammatory cytokines’ production
by DC, Mϕ, and T cells, and (b) provided antigen uptake,
processing, and presentation capacity to cells of the innate
immune system that led to the (c) activation of CD4+ helper
T cells and CD8+ polyfunctional, cytolytic T cells. Our data
suggest that (d) induction of antibody responses by vaccine is not
important for providing protection from infection, and instead
an interaction between APCs and adaptive T cell immunity
capable of expanding upon challenge infection is sufficient to
control T. cruzi dissemination.We also conclude that TcG2/TcG4
vaccine elicits highly effective anti-parasite immunity, and
inclusion of attenuated Tr (± QA) is not required to improve
the DNA vaccine’s efficacy against acute Tc infection. Future
studies should utilize parasites of different lineages, different
parasite inoculation size, and monitor all different tissues to
ensure that vaccine is fully protective. Our results also encourage
the designing of recombinant nano-plasmids that lack antibiotic
genes, can incorporate both TcG2 and TcG4 genes in one
plasmid, and are suitable for large-scale production; and testing
of the recombinant nano-plasmids as prophylactic or therapeutic
vaccine against T. cruzi in multiple hosts.
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Table S1 | Splenic and lymph node (LN) cell count post-vaccination.
Table S2 | Flow cytometry studies.
Figure S1 | Cross-reactivity of antibodies to T. rangeli in vaccinated mice.
C57BL/6 female mice were immunized with six different compositions of vaccines
as described in Materials and Methods. Mice were vaccinated with dose 1 at day
0, dose 2 at day 21, and euthanized at day 42. Vaccines (per dose) were
constituted with pCDNA3.TcG2 and pCDNA3.TcG4 (25 µg each plasmid DNA,
intramuscular), 1 × 108 T. rangeli fixed with 0.1 % glutaraldehyde (fTr,
subcutaneous), and 5 µg Quil A (QA, subcutaneous). Sera levels of T.
rangeli-specific IgG (A), IgG1 (B), IgG2A (C), and IgG2b (D) antibodies were
measured by an ELISA. Sera samples from normal and infected mice were used
as controls. Data (mean ± SD) are representative of two independent
experiments (n = 4 mice per group). Significance is annotated as ∗none vs.
vaccinated or infected vs. vaccinated/infected (∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001).
Figure S2 | Antigen presenting capacity of lymph node macrophages (Mϕ) in
vaccinated mice (± T. cruzi). Mice were vaccinated, infected and euthanized as in
Figure S1. Single cell suspensions of lymph node (LN) cells were labeled with
fluorochrome-conjugated antibodies, and analyzed by flow cytometry. Bar graphs
show ex vivo percentages of Ly6GloCD11b+ LN Mϕ that exhibited surface
expression of markers of maturation, antigen uptake, and antigen presentation
(CD205+, CD209+, MHCI+, MHCII+, CD80+) in vaccinated (A) and
vaccinated/infected (B) mice. Lymph node cells from non-vaccinated and
non-vaccinated/infected mice were used as controls. Data (mean ± SD) are
representative of two independent experiments (n = 3 mice per group per
experiment, duplicate observations per mouse). Significance is annotated as
∗none vs. vaccinated or infected vs. vaccinated/infected (∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001).
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